Cyclacel announces 1-for-16 reverse stock split effective May 12, 2025 to meet Nasdaq bid price requirement

Bio Green Med Solution, Inc.

Reverse split ratio of 1-for-16; effective May 12, 2025 at market open.
Pre-split shares: 356,357,531; post-split shares: 22,272,346 (rounded).
No fractional shares; rounding rules apply for shares half or more/less than half.
CUSIP changes to 23254L884; trading symbol remains CYCC on Nasdaq Capital Market.
Split approved by board and stockholders to regain compliance with Nasdaq minimum bid price.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bio Green Med Solution, Inc.: One-for-sixteen reverse stock split amendment to Certificate of Incorporation (effective 2025-05-12).

Change: charter amendment
Effective: 2025-05-12

Exact text from the filing

On May 7, 2025, Cyclacel Pharmaceuticals, Inc. (the “Company”) filed an amendment to its Certificate of Incorporation (“Certificate of Amendment”) to implement a one-for-sixteen reverse stock split.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-008988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.